相关实验视频
Updated: Jun 13, 2025

10:02
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
32.0K
通用竞争,价格和使用趋势的国际比较:韩国和G20国家
Da Hye Lee1, Jung-Ae Kim2, Kyung Min Lim1
1College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
Frontiers in public health
|June 11, 2025
概括
韩国 韩国 韩国 韩国
科学领域:
- 制药政策 制药政策
- 卫生经济学 卫生经济学
- 使用药物使用药物.
背景情况:
- 韩国具有较低的仿制药使用率和较高的支出份额,与全球趋势形成鲜明对比.
- 尽管进行了政策改革,但在韩国仿制药市场仍然存在挑战.
- 国际比较对于了解韩国仿制药政策的有效性至关重要.
研究的目的:
- 评估韩国仿制药政策的有效性.
- 为了比较韩国和G20国家之间的仿制药价格,竞争和使用情况.
- 确定导致韩国仿制药使用率低的因素.
主要方法:
- 在韩国和G20国家 (2014-2023) 对26种非专利活性成分的分析.
- 基于销售和数量数据 (2023) 计算仿制药价格.
- 通过计算可用的仿制药来评估仿制药竞争.
- 评估使用趋势,使用原始与仿制药的销售和数量比率.
主要成果:
- 韩国有更多的仿制药用于较旧的成分,但较少用于最近的非专利药物.
- 在韩国,通用药的价格通常较低,除了新的通用药.
- 与G20国家相比,韩国的仿制药销售和销量比率在韩国明显较低.
- 韩国市场份额更高的仿制药会导致价格更高.
结论:
- 韩国的仿制药政策是分散和低效的,阻碍了竞争和利用.
- 低效率会破坏仿制药价格,竞争和使用之间的积极循环.
- 政策建议包括优化支出,加强价格管理,加快开发,促进处方和使用仿制药.
相关概念视频
Drug Control Governance: Regulatory Bodies and Their Impact
145
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
145
Prescription, Nonprescription and Orphan Drugs
704
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
704
Drug Concentrations: Measurements
342
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
Plasma...
342
Analysis of Population Pharmacokinetic Data
239
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
239
Drug Nomenclature
1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K
Bioequivalence: Overview
942
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
942

